Development and characterization of a standardized adipogenesis assay for testing metabolism disrupting chemicals using human bone marrow derived mesenchymal stem cells
Ren XM., Chang RC., Amato AA., Huang Y., Yukimtiao B., Esser A.
Laboratory Study, published in NAM J (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- NAM J (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42369404
- PMCID
- PMC13288643
- DOI
- 10.1016/j.namjnl.2025.100029
Abstract (original English)
Obesity is a global health concern linked to various diseases. Recently, chemicals known as "obesogens" have been identified as significant contributors to obesity, highlighting the need for reliable methods to screen chemicals for their obesity-promoting potential. This study aimed to develop a standardized adipogenesis assay using primary human bone marrow-derived multipotent mesenchymal stromal stem cells (hBM-MSCs) to evaluate the adipogenic potential of chemicals. Lipid accumulation in hBM-MSCs was measured after chemical exposure. Assay conditions including cell confluency, fluorescent staining of neutral lipids and fluorometric detection were optimized and standardized. Using the established method, we evaluated the effects of six selected chemicals on the adipogenic responses of hBM-MSCs from different donors, including an in-house generated immortalized hBM-MSC cell line. Not all donor-derived hBM-MSCs were shown to be suitable for the assay, but we observed comparable results among suitable hBM-MSCs and between primary hBM-MSCs and their immortalized derivative cell line. Comparisons with the well-established 3T3-L1 preadipocyte model revealed a strong correlation with the hBM-MSCs assay. We observed that experimental details such as cell density, fluorescent measurement and cell donors can greatly affect outcomes; this stresses the importance of a well described stan
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.